Palliative treatment with electrochemotherapy in recurrent or metastatic vaginal cancer
| Autor: | Giulia Dondi, Andrea Galuppi, Alessandra De Palma, Anna Myriam Perrone, Alessio G. Morganti, Manuela Coe, Marco Tesei, Pierandrea De Iaco, Martina Ferioli, Francesca De Terlizzi |
|---|---|
| Přispěvatelé: | Perrone A.M., Ferioli M., Galuppi A., Coe M., de Terlizzi F., Tesei M., Dondi G., de Palma A., Morganti A.G., de Iaco P. |
| Rok vydání: | 2020 |
| Předmět: |
Leiomyosarcoma
Electrochemotherapy medicine.medical_specialty Vaginal Neoplasms Palliative care genital neoplasms female Vaginal neoplasm Bleomycin 03 medical and health sciences 0302 clinical medicine Humans Medicine Prospective Studies Neoplasm Metastasis Adverse effect Melanoma Aged Aged 80 and over Vaginal cancer Antibiotics Antineoplastic 030219 obstetrics & reproductive medicine business.industry Palliative Care Obstetrics and Gynecology Middle Aged medicine.disease Magnetic Resonance Imaging Surgery Oncology Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Carcinoma Squamous Cell Feasibility Studies Female Neoplasm Recurrence Local business Progressive disease |
| Zdroj: | International Journal of Gynecologic Cancer. 30:939-946 |
| ISSN: | 1525-1438 1048-891X |
| DOI: | 10.1136/ijgc-2020-001471 |
| Popis: | ObjectiveVaginal metastases are very rare events with a poor prognosis. To improve the quality of life, local treatments should be considered. The aim of this study was to evaluate the role of electrochemotherapy as palliative treatment in vaginal cancer not amenable to standard treatments due to poor performance status, previous treatments, or advanced disease.MethodsThis is a prospective observational study on patients diagnosed with vaginal cancer and treated from January 2017 to December 2018 with palliative electrochemotherapy. We collected data on patients with vaginal cancer treated by electrochemotherapy with the aim of local control. Data regarding electrochemotherapy, hospital stay, adverse events, and patient outcomes were analyzed. Intravenous bleomycin was injected as a bolus in 2–3 min at a dose of 15 000 UI/m2 and electrical pulses started 8 min after chemotherapy. Electrochemotherapy response was defined according to the Response Evaluation Criteria in Solid Tumors.ResultsFive patients with vaginal recurrence (two squamous, two melanomas, and one leiomyosarcoma) and one with vaginal metastasis from intestinal adenocarcinoma received one treatment and two patients were re-treated. Imaging reported nodal metastasis (inguinal or pelvic) in two patients, distant metastases in two, and both node and distant metastasis in two patients, respectively. Response Evaluation Criteria in Solid Tumors showed a complete response in one patient, partial response in three patients, stable disease in one patient, and progressive disease in one patient, with an overall response rate of 67% and a clinical benefit rate (complete response, partial response, stable disease) of 83%. Two patients were re-treated and had a new response (partial response and stable disease, respectively). At last follow-up, two patients had died of the disease, two were alive with stable disease, one was alive with progressive disease, and one was alive without disease. Median post-electrochemotherapy overall survival was 12.9 months (range 1.6–26.9) and 1-year overall survival was 66.7%.ConclusionsThis preliminary experience showed a tumor response or stabilization in 83% of patients requiring palliative management for vaginal cancer. Further studies are needed to evaluate treatment outcome in larger and prospective series. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|